Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients

Completed

Phase N/A Results

Summary of Purpose

To test the hypothesis that low-molecular-weight heparin Kabi 2165 in the dose of 2 X 2,500 anti-Xa units SC. would prevent thromboembolic complications in acute ischemic stroke patients.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 1 October 2001.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Trial Design

Double-blind, placebo-controlled, randomized trial of 60 patients.

Contacts

Not available